yil-781 has been researched along with Weight-Loss* in 2 studies
2 other study(ies) available for yil-781 and Weight-Loss
Article | Year |
---|---|
Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss.
Ghrelin, through action on its receptor, GH secretagogue receptor type 1a (GHS-R1a), exerts a variety of metabolic functions including stimulation of appetite and weight gain and suppression of insulin secretion. In the present study, we examined the effects of novel small-molecule GHS-R1a antagonists on insulin secretion, glucose tolerance, and weight loss. Ghrelin dose-dependently suppressed insulin secretion from dispersed rat islets. This effect was fully blocked by a GHS-R1a antagonist. Consistent with this observation, a single oral dose of a GHS-R1a antagonist improved glucose homeostasis in an ip glucose tolerance test in rat. Improvement in glucose tolerance was attributed to increased insulin secretion. Daily oral administration of a GHS-R1a antagonist to diet-induced obese mice led to reduced food intake and weight loss (up to 15%) due to selective loss of fat mass. Pair-feeding experiments indicated that weight loss was largely a consequence of reduced food intake. The impact of a GHS-R1a antagonist on gastric emptying was also examined. Although the GHS-R1a antagonist modestly delayed gastric emptying at the highest dose tested (10 mg/kg), delayed gastric emptying does not appear to be a requirement for weight loss because lower doses produced weight loss without an effect on gastric emptying. Consistent with the hypothesis that ghrelin regulates feeding centrally, the anorexigenic effects of potent GHS-R1a antagonists in mice appeared to correspond with their brain exposure. These observations demonstrate that GHS-R1a antagonists have the potential to improve the diabetic condition by promoting glucose-dependent insulin secretion and promoting weight loss. Topics: Animals; Appetite; Appetite Depressants; Cells, Cultured; Drug Evaluation, Preclinical; Ghrelin; Glucose Intolerance; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Models, Biological; Piperidines; Quinazolinones; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Ghrelin; Weight Loss | 2007 |
Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity.
The peptide hormone ghrelin is the endogenous ligand for the type 1a growth hormone secretagogue receptor (GHS-R1a) and the only currently known circulating appetite stimulant. GHS-R1a antagonism has therefore been proposed as a potential approach for obesity treatment. More recently, ghrelin has been recognized to also play a role in controlling glucose-induced insulin secretion, which suggests another possible benefit for a GHS-R1a antagonist, namely, the role as an insulin secretagogue with potential value for diabetes treatment. In our laboratories, piperidine-substituted quinazolinone derivatives were identified as a new class of small-molecule GHS-R1a antagonists. Starting from an agonist with poor oral bioavailability, optimization led to potent, selective, and orally bioavailable antagonists. In vivo efficacy evaluation of selected compounds revealed suppression of food intake and body weight reduction as well as glucose-lowering effects mediated by glucose-dependent insulin secretion. Topics: Administration, Oral; Animals; Binding, Competitive; Blood Glucose; Cell Line; Diabetes Mellitus; Eating; Glucose Tolerance Test; Humans; Male; Mice; Mice, Inbred C57BL; Obesity; Quinazolinones; Radioligand Assay; Rats; Rats, Wistar; Receptors, Ghrelin; Stereoisomerism; Structure-Activity Relationship; Weight Loss | 2007 |